Skip to main content

Table 1 Patient characteristics

From: Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition

Patient characteristics

Sex (female/male)

12/19

Age in years, median [range]

67 [25–83]

Height in meter, median [range]

1.70 [1.52–1.83]

Weight in kg, median [range]

74 [48–116]

Tumor type, n (%)

HCC

19 (61.3%)

No cirrhosis

5

Proven cirrhosis

14

NASH

7

ASH

4

HBV

1

HCV

1

Unknown etiology

4

CRC

6 (19.4%)

NET

3 (9.7%)

Pancreas

1 (3.2%)

Breast

1 (3.2%)

Stomach

1 (3.2%)

Portal vein embolism, n

Patients with PVE

2

Prior treatment, n (median months between last cycle and SIRT [min,max])

Systemic treatment

13 (1.0 [0.3, 15.2])

Anti-angiogenic

6 (9.7 [0.5, 16.6])

Anti-angiogenic (directly before SIRT)

3 (0.9 [0.5, 15.2])

Anti-angiogenic (not directly before SIRT)

3 (14.1 [5.3, 16.6])

Non anti-angiogenic

7 (0.7 [0.3, 13.4])

RFA/MWA

6 (13.8 [3.5, 31.0])

TACE

4 (8.3 [4.1, 48.3])

Resection

3 (14.4 [1.3, 41.9])

Volumes from prescription sheet (ml), median [range]

Total liver

1741 [789–4122]

Non-tumoral liver

1538 [682–2942]

Tumor

134 [0–2785]

Tumor burden

Median [range], %

8.8 [0.0–67.6]

< 5%, n (%)

10 (32%)

5–10%, n (%)

8 (26%)

10–25%, n (%)

8 (26%)

25-50%,n (%)

3 (10%)

> 50%,n (%)

2 (6%)

MAA work-up information

Lung shunt fraction (%)

8.0 [0.0–13.9]

Time from treatment in days, median [range]

18 [9–46]

Prescription method

Non-compartmental partition model, n (%)

16 (52%)

Compartmental partition model, n (%)

14 (45%)

Mixture of models, n (%)

1 (3%)

Treatment strategy

Whole liver, n (%)

2 (6%)

Bi-lobar, n (%)

15 (48%)

Mono-lobar, n (%)

10 (32%)

Selective (3 segments), n (%)

3 (10%)

Selective (4 segments), n (%)

1 (3%)

Prescribed activity

Total administered activity (GBq) [range]

1.527 [0.383–3.700]

Number of analyzed tumors (bigger than 5 ml)

Patients with 1 tumor, n (%)

16 (52%)

Patients with 2–3 tumors, n (%)

11 (35%)

Patients with more than 3 tumors, n (%)

4 (13%)

Analyzed LPTs information from prescription sheet

Total LPT (cc), median [range]

1001 [57–3172]

Non-tumoral liver (cc), median [range]

849 [0–2268]

Tumor (cc), median [range]

67 [0, 2785]

LPT to total liver ratio (%), median [range]

54 [3–100]

Tumor burden

Median [range], %

9.4 [0.0–100.0]

< 5%, n (%)

16 (34%)

5–10%, n (%)

9 (19%)

10–25%, n (%)

11 (23%)

25–50%, n (%)

8 (17%)

> 50%, n (%)

3 (6%)

Post-treatment image modality

PET/MR - PET/CT, n(%)

28 (90%) – 3 (10%)

  1. Aflibercept, Regorafenib, Bevacuzimab, or Sorafenib
  2. Octreotide LAR, FOLFOX, FOLFIRI, Cetuximab, De Gramont, TAS102, Avelumab, Paclitaxel, epirubicin + cisplatin + fluorouracil, Exemestane, Gemcitabine + abraxane, Everolimus, Letrozole, Trastuzumab, Pertuzumab, Panitumumab, Lanreotide